Program
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446
Its studies are led by Johnson & Johnson.
Furthest: phase 1, since Aug 5, 20251 company-led study, 1 open or runningNext primary completion: Nov 18, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 11 open or running | phase 1since Aug 5, 2025 | Aug 5, 2025 | Nov 18, 2027phase 1 · NCT07107230 |
- Named in Johnson & Johnson’s own pipeline as
JNJ-7446
, phase 1, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 5, 2025First study: phase 1 study in Advanced Stage Solid TumorsFirst studyNCT07107230 · 400 planned · United States, South Korea, Spain
Ahead
- Nov 18, 2027Primary completion: phase 1 study in Advanced Stage Solid TumorsNCT07107230
TargetBeta
“An antibody-drug conjugate (ADC) composed of amivantamab, a human bispecific immunoglobulin G1 (IgG1) antibody targeting the two tumor-associated antigens (TAAs) epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), linked to CPT-113, a dual-maleimide cleava…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of amivantamab, a human bispecific immunoglobulin G1 (IgG1) antibody targeting the two tumor-associated antigens (TAAs) epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
| TQB2922 | Sino Biopharmaceutical | phase 2 | 5 |
| TQB6411 | Sino Biopharmaceutical | phase 2 | 3 |
| Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101rule | VelaVigo Cayman | phase 2 | 1 |
| Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412rule | tavotek-biotherapeutics | phase 1 | 2 |
| HS-20122 | Hansoh Pharmaceutical Group | phase 1 | 2 |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902rule | BeOne Medicines | phase 1 | 1 |
| HLX48 | Fosun Pharma | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07107230Advanced Stage Solid Tumors · United States, South Korea, Spain | 1 | Recruiting | Nov 18, 2027 | 400 |
How it is read
Names in the registry
- “JNJ-95437446”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.